Hutchmed announced that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, or NHSA, on January 1, 2024 the updated National Reimbursement Drug List, or NRDL, will continue to include Elunate and Sulanda at the same terms as the current two-year agreement. Elunate was first included in the NRDL on January 1, 2020, for the treatment of metastatic colorectal cancer, or CRC. Sulanda was first included in the NRDL on January 1, 2022, for the treatment of non-pancreatic and pancreatic neuroendocrine tumors, or NETs. In China, there were an estimated 71,300 newly diagnosed NET patients in 2020, with potentially up to 300,000 patients living with the disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCM:
- HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
- HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
- Hutchmed upgraded to Buy from Hold at Deutsche Bank
- HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
